Viveve Medical, Inc. announced the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application 16/454,578 covering Viveve's unique dual-energy treatment to address SUI in women. The pending issuance of the new SUI patent further strengthens the Company's intellectual property portfolio in advance of the planned completion of its U.S. pivotal PURSUIT clinical trial by the end of the year and reporting of topline results in early 2023. Viveve's dual-energy technology has demonstrated its ability to activate fibroblasts and initiate collagen formation in tissue in a non-invasive, painless and comfortable procedure.

When applied to the areas surrounding the urethra, the technology's unique mechanism of action may strengthen and improve the function of connective tissues, improve vaginal structural integrity, and reduce urethral hypermobility, a leading cause of SUI in women.